Search

Displaying results 3561 - 3570 of 5506 in total
  1. Drug

    Luspatercept

    go.drugbank.com/drugs/DB12281
    ApprovedInvestigational

    [A187829,L42455] It was first approved for use in the United States in November 2019 under the brand name Reblozyl® for the treatment of anemia in patients with beta thalassemia who require regular blood … [L42455] Luspatercept is novel in that it ameliorates anemia via action on late-stage erythropoiesis, in contrast to typical erythropoiesis-stimulating agents (ESAs), such as [darbepoetin alfa] and [epoetin

  2. Drug

    NOX-700

    go.drugbank.com/drugs/DB05464
    Experimental

    It has since been found that oxidative signaling of the redox-sensitive transcription factor, NF-κB, and inhibiting protein glycation are responsible for the drug's therapeutic effects.

  3. Drug

    Metrizamide

    go.drugbank.com/drugs/DB01578
    Experimental

    It is also used as a resorbable, non-ionic contrast medium.

  4. Drug

    Cryptenamine

    go.drugbank.com/drugs/DB00785
    Approved

    It has been used in the treatment of hypertension but has largely been replaced by drugs with fewer adverse effects.

  5. Drug

    PRO 2000

    go.drugbank.com/drugs/DB05385
    Investigational

    It is being studied for the prevention of HIV infection and other sexually transmitted diseases. … PRO 2000 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials.

  6. Drug

    Xanthine

    go.drugbank.com/drugs/DB02134
    Investigational

    (Dorland, 28th ed) … It is an intermediate in the degradation of adenosine monophosphate to uric acid, being formed by oxidation of hypoxanthine.

  7. Drug

    Dactinomycin

    go.drugbank.com/drugs/DB00970
    ApprovedInvestigational

    It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release.

  8. Drug

    Gemifloxacin

    go.drugbank.com/drugs/DB01155
    ApprovedInvestigational

    It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth.

  9. Drug

    Chromium Cr-51

    go.drugbank.com/drugs/DB11140
    ApprovedInvestigational

    It is used as a diagnostic radiopharmaceutical agent in nephrology to determine glomerular filtration rate,[A249765,A249770] and in hematology to determine red blood cell volume or mass, study the red

  10. Drug

    Ethylenediamine

    go.drugbank.com/drugs/DB14189
    Approved

    It is also used as an excipient in many pharmacological preparations such as creams. Notably, ethylenediamine is a contact sensitizer capable of producing local and generalized reactions [A34285].